Search

MannKind Corp

Geschlossen

BrancheGesundheitswesen

3.29 -3.52

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.24

Max

3.3

Schlüsselkennzahlen

By Trading Economics

Einkommen

-2.4M

-19M

Verkäufe

19M

109M

KGV

Branchendurchschnitt

140.5

47.946

EPS

-0.06

Gewinnspanne

-17.401

Angestellte

591

EBITDA

10M

13M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+121.01% upside

Dividenden

By Acuity

Nächstes Ergebnis

4. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

54M

1.2B

Vorheriger Eröffnungskurs

6.81

Vorheriger Schlusskurs

3.29

MannKind Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

9. Okt. 2026, 20:01 UTC

MannKind Corp shares are declining, continuing a downward trend with notable volatility, hitting a low point around mid-afternoon amid broader market weakness.

8. Okt. 2026, 20:07 UTC

MannKind Corp shares are declining, retracing from an earlier rally and closing lower compared to Wednesday's close, continuing to trade below its 20-day moving average.

7. Okt. 2026, 20:00 UTC

News

MannKind shares fell sharply as Truist Securities lowered its price target to $5.00 from $6.00 while maintaining a Buy rating.

6. Okt. 2026, 19:55 UTC

MannKind Corp shares fell sharply, continuing a decline since Monday's close, despite remaining above its 20-day moving average.

5. Okt. 2026, 21:01 UTC

MannKind Corp's shares declined during after-market hours on Monday, moving lower after a stable start and contrasting with recent performance above the 20-day moving average.

2. Okt. 2026, 23:05 UTC

MannKind Corp is trading modestly higher in after-market hours, reflecting typical fluctuations as it remains near the midpoint of its one-month trading range.

1. Okt. 2026, 21:01 UTC

MannKind Corp is declining in after-market trading, retracing from its opening level and hitting its lowest point shortly after the session began.

30. Sept. 2026, 23:00 UTC

MannKind Corp is trading higher in after-market hours, supported by stronger-than-expected GDP growth and a rise in private sector job additions in September.

29. Sept. 2026, 20:07 UTC

MannKind Corp's shares fell sharply, continuing a downward trend since Monday, and remain significantly below their 20-day moving average.

28. Sept. 2026, 20:41 UTC

MannKind Corp's shares declined in after-market trading, continuing a downward trend since Monday's close and remaining below its 20-day moving average.

25. Sept. 2026, 20:21 UTC

MannKind Corp's shares declined in after-market trading, significantly below its 20-day moving average and near the lower end of its one-month range.

24. Sept. 2026, 20:07 UTC

MannKind Corp's shares fell sharply, continuing a trend with five consecutive lower daily closes and remaining significantly below the 20-day moving average.

23. Sept. 2026, 23:01 UTC

MannKind Corp's shares are trading higher in after-market hours, recovering from earlier losses but remain below their 20-day moving average.

22. Sept. 2026, 23:31 UTC

MannKind Corp is experiencing a notable decline in after-market trading, shifting from a slight gain to a significant loss since Tuesday's close.

21. Sept. 2026, 23:31 UTC

MannKind Corp's shares are advancing in after-market trading, reflecting a notable rise since Monday's close, though still below the 20-day moving average.

18. Sept. 2026, 20:06 UTC

MannKind Corp's shares fell sharply after an early spike, remaining below the 20-day moving average and near the lower end of their one-month range.

17. Sept. 2026, 19:46 UTC

News

MannKind Corp is trading roughly flat as analysts give it an average "Moderate Buy" rating, with seven out of ten firms issuing buy recommendations.

16. Sept. 2026, 23:52 UTC

MannKind Corp is seeing higher after-market trading, reflecting broader market gains despite concerns over TIC outflows and rising Treasury yields.

15. Sept. 2026, 22:02 UTC

MannKind Corp shares are lower in after-market hours, reflecting broader market weakness and concerns from a decline in the NY Empire State Manufacturing Index.

14. Sept. 2026, 19:16 UTC

News

MannKind Corp shares are lower amid mixed analyst ratings and broader market declines, as inflation concerns and supply chain disruptions weigh on sentiment.

11. Sept. 2026, 19:46 UTC

News

MannKind Corp shares are lower today amid broader market trends and inflation data, marking a third consecutive session of declines.

10. Sept. 2026, 22:01 UTC

MannKind Corp shares are higher in after-market trading, reflecting notable gains since Thursday's close, though still below the 20-day moving average.

9. Sept. 2026, 20:01 UTC

Social Media
News

MannKind Corp shares are lower after announcing a licensing deal with Rose Pharma for the development of ROSE-010, an inhaled GLP-1 receptor agonist.

8. Sept. 2026, 20:07 UTC

News

MannKind Corp's shares are higher today amid mixed analyst ratings, including a downgrade from Zacks and a price target increase from Royal Bank of Canada.

4. Sept. 2026, 19:36 UTC

MannKind Corp's shares are advancing, recovering from earlier volatility. The stock is currently above its 20-day moving average amid a stable one-month trading range.

3. Sept. 2026, 23:26 UTC

MannKind Corp shares are higher in after-market trading, reflecting broader market strength amid reduced rate hike expectations. Major indices reported substantial gains.

1. Sept. 2026, 20:08 UTC

MannKind Corp's shares are lower amid a broader market downturn and rising oil prices, which have heightened inflation concerns and interest rate hike expectations.

31. Aug. 2026, 23:56 UTC

MannKind Corp shares are lower in after-market trading, continuing a trend observed over the past four sessions amid rising oil prices and inflation concerns.

28. Aug. 2026, 20:07 UTC

MannKind Corp shares are lower today, extending a three-day decline amid rising U.S. Treasury yields and broader equity market concerns.

27. Aug. 2026, 19:46 UTC

MannKind Corp. shares are trading roughly flat, with no specific news identified. The stock remains around the middle of its one-month trading range.

Peer-Vergleich

Kursveränderung

MannKind Corp Prognose

Kursziel

By TipRanks

121.01% Vorteil

12-Monats-Prognose

Durchschnitt 7.559 USD  121.01%

Hoch 13 USD

Tief 4.16 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für MannKind Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

7 ratings

6

Buy

1

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.